Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 7/20 | 0.41 |
| ▸ | TACR1 | P25103 | 6/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6812559 | 0.93 | TACR2 (0.41) | TACR2TACR1ITGA4ITGB7ITGB1 | |
| SCHEMBL6804225 | 0.93 | TACR2 (0.50) | TACR2TACR1ITGA4ITGB7ITGB1 | |
| SCHEMBL6806435 | 0.92 | TACR2 (0.40) | TACR2TACR1ITGA4ITGB7ITGB1 | |
| SCHEMBL6807420 | 0.90 | ITGB2 (0.43) | TACR2TACR1ITGA4ITGB1KMT2A | |
| SCHEMBL6807296 | 0.90 | TACR2 (0.42) | TACR2TACR1ITGA4ITGB7ITGB1 | |
| SCHEMBL6808176 | 0.90 | TACR2 (0.40) | TACR2TACR1ITGA4ITGB7ITGB1 | |
| SCHEMBL6807057 | 0.90 | TACR2 (0.39) | TACR2TACR1ITGA4ITGB7ITGB1 | |
| SCHEMBL6802798 | 0.90 | ITGB1 (0.41) | TACR2TACR1ITGA4ITGB1ITGB2 | |
| SCHEMBL6808899 | 0.88 | KMT2A (0.41) | ITGA4ITGB1KMT2AP2RY12ECE1 | |
| SCHEMBL6802705 | 0.87 | KMT2A (0.42) | ITGA4ITGB1KMT2AITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | TACR2 2639/4885TACR1 2733/4885ITGA4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.